2 results
Approved WMOCompleted
To determine the efficacy and safety of adding transdermal nitroglycerin to first line chemotherapy for advanced NSCLC.
Approved WMOCompleted
PHASE IIPrimary ObjectiveThe primary objective of the Phase II portion of the study is to estimate the efficacy as measured by radiographic progression-free survival of IPATASERTIB (GDC-0068) (dosed at either 400 mg or 200 mg daily) + abiraterone…